Donanemab slowed cognitive, functional ability declines in early Alzheimer’s disease, according to top-line data from a Phase 3 trial.| Alzheimer's News Today
Kisunla (donanemab-azbt) is an antibody-based therapy approved in the U.S. for adults with early symptomatic Alzheimer’s disease.| Alzheimer's News Today
Columnist Ray Burow explains how her mother's Alzheimer's called to mind Dickens' quote about the "spring of hope" and "winter of despair."| Alzheimer's News Today
Category archive page for Columns.| Alzheimer's News Today
Learn more about Alzheimer's disease, the most common cause of dementia and an irreversible, progressive neurological disorder.| Alzheimer's News Today